The DJS Law Group filed the complaint alleging that Erasca violated the Securities Exchange Act by issuing false statements about its internal pipeline. According to the court documents, the firm’s public optimism surrounding ERAS-0015 lacked a factual foundation and masked significant risks regarding patent infringement. These omissions allegedly left shareholders exposed to financial losses when the underlying issues surfaced.
In section Releases
Erasca Faces Securities Class Action Over Misleading Drug Claims
Investors who purchased Erasca, Inc. shares between January 14, 2025, and April 26, 2026, are being urged to join a class action lawsuit. The litigation alleges the company misled the market regarding the development and patent risks associated with its ERAS-0015 therapeutic candidate.
Those who held stock during the specified period have until August 10, 2026, to contact legal counsel regarding their eligibility to serve as lead plaintiff. While joining the action does not guarantee a recovery, the firm emphasizes that participation is a standard step for institutional and individual investors seeking to recoup losses linked to the company's market disclosures.
Comments (0)
No comments yet. Be the first!